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ARTICLE
A single-dose live-attenuated vaccine prevents
Zika virus pregnancy transmission and testis
damage
Chao Shan1, Antonio E. Muruato2, Brett W. Jagger3, Justin Richner3, Bruno T.D. Nunes1,4,
Daniele B.A. Medeiros1,4, Xuping Xie1, Jannyce G.C. Nunes1,4, Kaitlyn M. Morabito5, Wing-Pui Kong5,
Theodore C. Pierson6, Alan D. Barrett7,8,9,10, Scott C. Weaver2,10,11,12, Shannan L. Rossi7,8,9,
Pedro F.C. Vasconcelos4,13, Barney S. Graham6, Michael S. Diamond3,14,15,16 & Pei-Yong Shi1,10,11,13,17
Zika virus infection during pregnancy can cause congenital abnormities or fetal demise. The
persistence of Zika virus in the male reproductive system poses a risk of sexual transmission.
Here we demonstrate that live-attenuated Zika virus vaccine candidates containing deletions
in the 3′ untranslated region of the Zika virus genome (ZIKV-3′UTR-LAV) prevent viral
transmission during pregnancy and testis damage in mice, as well as infection of nonhuman
primates. After a single-dose vaccination, pregnant mice challenged with Zika virus at
embryonic day 6 and evaluated at embryonic day 13 show markedly diminished levels of viral
RNA in maternal, placental, and fetal tissues. Vaccinated male mice challenged with
Zika virus were protected against testis infection, injury, and oligospermia. A single immu-
nization of rhesus macaques elicited a rapid and robust antibody response, conferring
complete protection upon challenge. Furthermore, the ZIKV-3′UTR-LAV vaccine candidates
have a desirable safety proﬁle. These results suggest that further development of ZIKV-3′
UTR-LAV is warranted for humans.
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Zika virus (ZIKV) belongs to the Flavivirus genus in theFlaviviridae family, and is closely related to other globallyimportant ﬂaviviruses, including dengue, yellow fever,
Japanese encephalitis, West Nile, and tick-borne encephalitis
viruses1. Flaviviruses have a single-stranded, positive-sense RNA
genome consisting of a 5′ untranslated region (UTR), a single
open reading frame (ORF), and a 3′UTR. The single ORF
encodes three structural (C-prM/M-E) and seven nonstructural
(NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5) proteins. ZIKV is
transmitted primarily by peridomestic Aedes mosquitoes, but also
can be acquired through sexual, vertical, and blood transfusion
routes2, 3. Although only about 20% of infected individuals
develop clinical sign or symptoms, ZIKV infection in some adults
is associated with the development of Guillain–Barré syndrome4.
The most devastating manifestation of ZIKV infection is the array
of congenital abnormalities in the fetuses and infants of women
infected while pregnant, including microcephaly, craniofacial
disproportion, spasticity, seizures, ocular abnormalities, cerebral
calciﬁcation, and miscarriage5, 6. Longitudinal studies in humans
in Brazil showed that among live infants born to symptomatic
ZIKV-positive women, 42% had grossly abnormal clinical or
brain imaging ﬁndings5. Furthermore, ZIKV infection can persist
in the male reproductive tract, as infectious virus and viral RNA
have been detected in semen up to 69 and 188 days after
symptom onset, respectively7–9; infected males can transmit virus
to sexual partners during this period of persistent infection10.
Studies in mice have shown that ZIKV persistence in the testis
causes damage to the seminiferous tubules, testicular atrophy,
oligospermia, and reduced rates of fertility11–13. A number of
promising ZIKV vaccine platforms have been developed,
including inactivated, subunit (prM-E proteins expressed from
DNA, RNA, or viral vectors), and live-attenuated vaccines14–21,
several of which have entered phase I-II clinical trials22, 23.
Among these vaccine candidates, the prM-E RNA vaccine and
live-attenuated vaccine (lacking NS1 glycosylations) were recently
shown to protect against vertical transmission in a mouse preg-
nancy model24. In addition, the DNA vaccine expressing prM-E
proteins was recently shown to protect mice against ZIKV-
induced damages to testes25.
Here we show that live-attenuated ZIKV vaccine candidates
containing deletions in the 3′UTR of the ZIKV genome (ZIKV-3′
UTR-LAV) prevent viral transmission during pregnancy and
testis damage in mice, as well as infection of nonhuman primates
(NHPs). We also demonstrate a desirable safety proﬁle of the
vaccine candidates. Our data suggest that ZIKV-3′UTR-LAV
merits further development for humans.
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Fig. 1 ZIKV-3′UTR-Δ10-LAV protects pregnant C57BL/6 mice and their developing fetuses. a Scheme of immunization of wild-type (WT) C57BL/6 female
mice with 105 FFU of ZIKV-3′UTR-Δ10-LAV (Δ10; n= 12) or PBS sham (n= 16). b Serum was collected at day 28 post immunization and analyzed for
neutralizing activity using an mCherry infectious ZIKV. Representative neutralization curves are shown. Error bars denote the SD of duplicate technical
replicates. c NT50 values of neutralizing antibodies were measured for individual animals. The dashed lines indicate the limit of detection (LOD) of the assay.
d–g At day 35 post immunization, vaccinated female mice were mated with WT C57BL/6 males. A subset of the female mice developed vaginal plugs.
Pregnant mice (n= 8 pooled from two independent experiments) were administered 2mg of anti-Ifnar1 blocking antibody on E5, and 1 day later (E6),
challenged with 105 FFU of a pathogenic, mouse adapted ZIKV Dakar 41519 strain. On E13, animals were euthanized; maternal spleen (d), maternal
brain (e), placenta (f), and fetal heads (g) were harvested and quantiﬁed for viral RNA levels. Median viral RNA levels are indicated for each group.
Asterisks indicate signiﬁcant differences (Mann–Whitney test: ****P-value < 0.0001). All negative samples are plotted at the half value of LOD.
The results in the Figure are pooled from two independent experiments
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Results
Prevention of vertical transmission in pregnant mice.
We recently developed a live-attenuated vaccine candidate
containing a 10-nucleotide deletion in the 3′UTR of ZIKV
genome (ZIKV-3′UTR-Δ10-LAV); this vaccine conferred nearly
sterilizing immunity after a single-dose immunization and
showed an excellent safety proﬁle in mice19. To test the ability
of this vaccine candidate to prevent in utero transmission,
we subcutaneously inoculated 105 focus-forming units (FFU) of
ZIKV-3′UTR-Δ10-LAV or Phosphate Buffered Saline (PBS-
sham) into 8-week-old wild-type (WT) C57BL/6 female mice
(Fig. 1a). Because mice are not a native host for ZIKV due in part
to a species-dependent lack of antagonism of type I interferon
(IFN) signaling26, 27, we administered 0.5 mg of anti-IFN alpha/
beta receptor 1 (anti-Ifnar1) blocking antibody to female mice
1 day prior to vaccination to facilitate transient replication of
ZIKV-3′UTR-Δ10-LAV28. At day 28 post-vaccination, the ani-
mals were phlebotomized and serum was analyzed for neu-
tralizing antibody (Fig. 1b); all ZIKV-3′UTR-Δ10-LAV-
immunized mice developed high neutralizing antibody titers of
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Fig. 2 ZIKV-3′UTR-Δ10-LAV protects young A129 male mice against testis infection and injury. a Scheme of immunization of 3-week-old A129 male mice with
104 FFU of ZIKV-3′UTR-Δ10-LAV (Δ10; n= 6) or PBS sham (n= 4 or 6). At day 28 post immunization, mice were measured for neutralization antibody titers.
On the same day, mice from one sham group and mice from Δ10-immunized group were challenged with 106 FFU of ZIKV-PRVABC59, and viremia was
measured at day 2 post challenge (day 30 post immunization). At day 49 post immunization, mice were analyzed for sperm counts and viral load in the testis.
b Viremia after immunization with Δ10 vaccine candidate. c NT50 values of antibody neutralization at day 28 post immunization were measured for individual
animals in each group. The dashed lines indicate the limit of detection (LOD) of the assay. d Viremia at day 2 post challenge (day 30 post immunization) with
ZIKV PRVABC59. e Viral load in the testis at day 21 post challenge (day 49 post immunization). f, g Total (f) and motile (g) sperm counts at day 21 post
challenge. h, i Testis weight (h) and representative images of testis (i) from animals from sham, sham with challenge, and Δ10-immunized and challenged
groups at day 21 post challenge. Scale bar, 1 mm. Asterisks indicate signiﬁcant differences (one-way ANOVA: ****P-value <0.0001; ***P-value <0.001).
Nonsigniﬁcant (n.s.), P-value >0.05. All negative samples are plotted at the half value of LOD. Error bars represent SDs
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18,900± 5900 (mean± SD; n= 13), whereas, as expected, the
PBS-immunized animals did not develop detectable
neutralizing antibodies (Fig. 1c). At day 35 post vaccination,
the immunized females were mated with 12-week-old WT
C57BL/6 male mice and monitored for vaginal plugs (Fig. 1a).
At embryonic day 6 (E6), pregnant mice were challenged
subcutaneously with 105 FFU of a mouse-adapted, pathogenic
ZIKV African strain Dakar 4151929; to facilitate ZIKV-Dakar
dissemination to the maternal decidua and fetal placenta, the
pregnant mice were administered 2 mg of anti-Ifnar1 antibody at
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E5, 1 day before the challenge. At E13, maternal and fetal organs
were harvested and measured for viral load.
After a single immunization, ZIKV-3′UTR-Δ10-LAV
reduced median viral loads in the maternal spleen and brain by
~49,000-fold and ~120-fold, respectively (Fig. 1d, e). Placentas and
fetal heads from the vaccinated dams showed 138,000-fold and
260-fold decreases in viral RNA loads, respectively, when
compared with the PBS-immunized dams (Fig. 1f, g). Notably,
21 of 30 (70%) placentas and 21 of 30 (70%) fetal heads from
ZIKV-3′UTR-Δ10-LAV-immunized dams had viral RNA loads at
or below the detection limit; no infectious virus was recovered by
focus-forming assay from the placentas or fetal heads from the
vaccinated dams (Supplementary Fig. 1a, b). In addition, the
immune correlate between the NT50 values and the levels of
infectious viruses detected in the placenta revealed an expected
inverse relationship between neutralizing titers and levels of ZIKV
particles in placenta (Supplementary Fig. 1c). Collectively, the data
suggest that ZIKV-3′UTR-Δ10-LAV protects maternal organs
from infection, prevents viral transmission to the fetus during an
early stage of pregnancy, and limits fetal virus replication.
Protection of ZIKV-induced damages to testes. We examined
the ability of ZIKV-3′UTR-Δ10-LAV to prevent testis infection and
injury in Ifnar1−/− A129 mice (Fig. 2a). Since male mice reach
sexual maturity at 8 weeks of age, we tested the vaccine efﬁcacy in
two age groups of mice: 3-week-old young males; and 15-week-old
adult males. Three-week-old young A129 male mice were vacci-
nated with a single-dose of 104 FFU of ZIKV-3′UTR-Δ10-LAV or
PBS sham. The ZIKV-3′UTR-Δ10-LAV generated a peak viremia
of 1.2± 0.34 × 104 FFU (n= 6) at day 4 post vaccination (Fig. 2b).
At day 28 post vaccination, ZIKV-3′UTR-Δ10-LAV had
induced robust neutralizing antibody titers of 7700± 2600 (n= 6;
Fig. 2c). At the same day, the animals were challenged intraper-
itoneally with 106 FFU of an epidemic ZIKV strain from
Puerto Rico (PRVABC59). No viremia was detected from the
ZIKV-3′UTR-Δ10-LAV-vaccinated mice after challenge, whereas
the sham-vaccinated animals sustained a mean peak viremia of
7.1± 5.9 × 106 FFU/ml (n= 6) at day 2 post challenge (Fig. 2d). At
day 21 post challenge, viral burden in the testis of PBS-immunized
mice reached 5.8± 8.4 × 106 FFU/g (n= 6), whereas no infectious
virus was detected in the testes of ZIKV-3′UTR-Δ10-LAV-immu-
nized mice (Fig. 2e). Both total and motile sperm counts from the
ZIKV-3′UTR-Δ10-LAV-immunized mice were equivalent to those
from age-matched unvaccinated, unchallenged healthy male mice.
In contrast, the PBS-immunized, ZIKV-challenged mice showed
85% and 90% reductions for total and motile sperm counts,
respectively, at day 21 post infection (Fig. 2f, g). Consistent with
these data, the testis weight and size from the PBS-immunized,
ZIKV-challenged mice were reduced, whereas no such
reduction was observed in the ZIKV-3′UTR-Δ10-LAV-immunized,
ZIKV-challenged animals (Fig. 2h, i).
In 15-week-old adult A129 male mice, vaccination with
ZIKV-3′UTR-Δ10-LAV also protected against testis infection,
injury, and oligospermia (Supplementary Fig. 2a–g). However,
challenge of the PBS-vaccinated adult males with
ZIKV PRVABC59 did not reduce the testis weight and size
(Supplementary Fig. 2h, i) as much as that observed in the
corresponding sham-vaccinated, young males (Fig. 2h, i),
suggesting an age-dependent testis pathology. Collectively,
the results indicate that a single-dose immunization of
ZIKV-3′UTR-Δ10-LAV protects the testis from infection and
injury in male mice.
Efﬁcacy in NHPs. To determine whether the efﬁcacy in mice
extends to NHPs, we evaluated the viremia, immunogenicity,
and potency of ZIKV-3′UTR-Δ10-LAV in rhesus macaques
(RMs; Fig. 3a). First, we assessed the level of attenuation of
ZIKV-3′UTR-Δ10-LAV in RMs by comparing viremia to the
parental WT virus. After subcutaneous inoculation with 103 FFU,
WT ZIKV (2010 Cambodian strain FSS 13025) produced high
levels of viremia in each of the four inoculated RMs, with a mean
peak viremia of 9.6 × 104 and 2.88 × 105 genome copies/ml at
days 4 and 5 post infection, respectively (Fig. 3b, top panel). In
contrast, only one of the four ZIKV-3′UTR-Δ10-LAV-inoculated
RMs exhibited viremia, and this level was just above the limit
of detection of our quantitative reverse transcriptase-PCR
(qRT-PCR) assay (Fig. 3b, second panel); thus, ZIKV-3′UTR-
Δ10-LAV is highly attenuated in RMs. We next evaluated the
immunogenicity of ZIKV-3′UTR-Δ10-LAV by measuring
neutralizing antibodies from serum at days 5–98 post immuni-
zation. Neutralizing antibodies elicited by WT ZIKV were
detectable at day 7–10, peaked at 1/1000–1/10,000 at day 14, and
plateaued thereafter (Fig. 3c, top panel). Compared with the WT
ZIKV infection, ZIKV-3′UTR-Δ10-LAV-inoculated animals
showed slightly delayed production and lower levels of neu-
tralizing antibody, with titers of ~1/100 at days 21–56 (Fig. 3c,
second panel). At day 56 post immunization, all RMs were
challenged with 103 FFU of the epidemic ZIKV strain
PRVABC59. Notably, no viremia was detected upon challenge in
any of the RMs that were pre-infected with WT ZIKV or vacci-
nated with the ZIKV-3′UTR-Δ10-LAV (Fig. 3d, top two panels).
As controls, two PBS-inoculated RMs were challenged in parallel
and high levels of viremia were measured (Fig. 3d, bottom panel).
In addition to analysis of viral RNA by qRT-PCR, we also
performed focus-forming assays to measure infectious virus;
infectious ZIKV was detected only in naive RMs challenged with
WT ZIKV (Supplementary Fig. 3).
To examine whether the ZIKV challenge resulted in boosted
immune responses, we measured neutralizing activity post
challenge. No increase in neutralizing activity was observed in
the WT ZIKV-vaccinated RMs after challenge (Fig. 3c, top panel),
indicating that the initial infection likely conferred
sterilizing immunity. In contrast, the neutralizing antibody
titers rose after challenge from ~1/100 to 1/1000–1/10,000
in the ZIKV-3′UTR-Δ10-LAV-immunized animals (Fig. 3c,
second panel), demonstrating an anamnestic response and
suggesting a low level of infection after challenge that was
not detectable by qRT-PCR of serum. As expected, the
PBS-inoculated control RMs increased their neutralizing titers
to ~1/10,000 after challenge (Fig. 3c, bottom panel).
Fig. 3 ZIKV-3′UTR-Δ10-LAV and ZIKV-3′UTR-Δ20-LAV protect rhesus macaques (RMs) from ZIKV infection. a Scheme of immunization of RMs with 103
FFU of WT ZIKV strain FSS13025 (n= 4), ZIKV-3′UTR-Δ10-LAV (Δ10; n= 4), ZIKV-3′UTR-Δ20-LAV (Δ20; n= 3), ZIKV-NS1-LAV or PBS sham (n= 2)
via the subcutaneous route. b Viremia was measured at days 2, 3, 4, 5, 7, and 10 post immunization by qRT-PCR. Each colored line represents data from a
different animal in each group. The dashed line indicates the limit of detection (LOD) of the assay. c Pre- and post-challenge antibody neutralization titers.
On various days post immunization, sera were measured for neutralizing titers using an mCherry ZIKV infection assay. Red arrows indicate challenge with
103 FFU of epidemic ZIKV strain PRVABC59 via the subcutaneous route at day 56 post immunization. The number of animals whose antibody
neutralization titers increased by ≥ 4-fold after challenge is indicated by symbol “↑” for each experimental group. d Post-challenge viremia. Viremia was
measured by qRT-PCR at days 2, 3, 4, 5, 7, and 10 post challenge. All negative samples are plotted at the half value of LOD. Error bars represent SDs
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Since ZIKV-3′UTR-Δ10-LAV did not elicit sterilizing immu-
nity in RMs, we evaluated whether a second live-attenuated
vaccine candidate ZIKV-3′UTR-Δ20-LAV19, which contains
a 20-nucleotide deletion in the 3′UTR, could induce a stronger
immune response. ZIKV-3′UTR-Δ20-LAV was shown
previously, and paradoxically, to be less attenuated than ZIKV-
3′UTR-Δ10-LAV in A129 mice, most likely because it is less
sensitive to type I IFN inhibition compared to ZIKV-3′UTR-Δ10-
LAV19. After subcutaneous inoculation of 103 FFU of ZIKV-3′
UTR-Δ20-LAV, two of the three RMs had low, but detectable
viremia (Fig. 3b, third panel). The immunized animals rapidly
produced neutralizing antibodies by day 10, with inhibitory titers
plateauing at 1/1000–1/10,000 by days 14–21 (Fig. 3c, third
panel). After challenge with 103 FFU of ZIKV PRVABC59 at day
56, viremia was not detected by qRT-PCR (Fig. 3d, third panel)
and no rise in neutralizing antibody titers was observed (Fig. 3c,
third panel) in the ZIKV-3′UTR-Δ20-LAV-immunized animals.
Although low number of animals were used for each vaccine
candidate, the results suggest that a single-dose vaccination of
ZIKV-3′UTR-Δ20-LAV induces sterilizing immunity in NHPs
(i.e., no detectable viremia and no increase of neutralizing
antibody titer after challenge).
We also evaluated another live-attenuated ZIKV vaccine
candidate encoding an NS1 without glycosylation (ZIKV-NS1-
LAV) in RMs. ZIKV-NS1-LAV was recently shown to prevent
in utero transmission in a mouse pregnancy model24. After
subcutaneous immunization of four RMs with 103 FFU of ZIKV-
NS1-LAV, none of the animals showed any detectable viral RNA
(Fig. 3b, fourth panel). Back titering of the ZIKV-NS1-LAV
inoculum using a focus-forming assay conﬁrmed the infectivity
of viral stock with the expected infectious titer. Unexpectedly,
the immunization did not ellicit any neutralizing activity
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Fig. 4 Safety evaluation of ZIKV-3′UTR-Δ20-LAV (Δ20) vaccine candidate. a Viral loads in organs of infected A129 mice. Three-week-old A129 mice
(n= 7) were subcutaneously immunized with 103 FFU of WT ZIKV FSS13025 (left panel) and its derivative Δ20 vaccine candidate (right panel).
Organs from infected mice were collected and homogenized at days 6 and 10 post infection. The amounts of viruses were quantiﬁed on Vero cells using
a focus-forming assay. The mean results from seven animals are presented. Bars denote standard errors. The dashed lines indicate the limit of detection
(LOD) of the assay. b–f Effect of Δ20 vaccination on the testis. Three-week-old A129 mice (n= 5) were subcutaneously infected with 1 × 103 FFU of WT
ZIKV FSS13025 or Δ20 vaccine candidate. At day 28 post infection, animals from each group were analyzed for testis weight (b), testis size (c),
total sperm counts (d), motile sperm counts (e), and viral RNA load (f). Scale bar, 1 mm. g Comparison of neurovirulence of WT ZIKV FSS13025 and Δ20
vaccine candidate in outbred CD-1 mice. One-day-old CD-1 mice (n= 7–8/group) were injected intracranially with 10–104 FFU of WT ZIKV or 103–104 FFU
of Δ20 vaccine candidate. Surviving mice and total infected animals are indicated. h Analysis of vector competency. Aedes aegypti were fed on artiﬁcial
blood-meals spiked with 106 FFU/ml of WT ZIKV FSS13025 or Δ20 vaccine virus. At day 7 post feeding, individual engorged mosquitoes were assayed for
infection by immunostaining of viral protein expression on inoculated Vero cells. The number of infected mosquitos and total number of engorged
mosquitoes are indicated. Asterisks indicate signiﬁcant differences (one-way ANOVA: ***P-value < 0.001; **P-value < 0.01; *P-value < 0.05).
Nonsigniﬁcant (n.s.) with P-value > 0.05. All negative samples are plotted at the half value of LOD. Error bars represent SDs
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(Fig. 3c, fourth panel). After challenge with 103 FFU of ZIKV
PRVABC59 at day 56, all four animals displayed robust
viremia (Fig. 3d, fourth panel) and generated neutralizing
antibody titers (Fig. 3c, fourth panel). The results indicate that
ZIKV-NS1-LAV is incapable of replicating and triggering anti-
body response in RMs.
Testis protection and safety analysis of ZIKV-3′UTR-Δ20-
LAV. Because of the highly desirable sterilizing immunity
induced by ZIKV-3′UTR-Δ20-LAV in RMs, we further tested its
efﬁcacy and safety. Similar to ZIKV-3′UTR-Δ10-LAV, immuni-
zation of male A129 mice with 103 FFU of ZIKV-3′UTR-Δ20-
LAV completely prevented viral infection and testis injury after
challenge with ZIKV PRVABC59, as determined by a lack of
detectable viremia post challenge, the absence of oligospermia,
and no decrease in testis weight and size (Supplementary Fig. 4).
Next, ﬁve sets of experiments were performed to characterize the
safety of ZIKV-3′UTR-Δ20-LAV. First, we measured the organ
viral loads after subcutaneous inoculation of A129 mice with 103
FFU of ZIKV-3′UTR-Δ20-LAV or parental WT ZIKV (Fig. 4a).
At day 6 post infection, WT ZIKV-infected mice exhibited high
viral loads in all tested organs, whereas no infectious virus was
detected (≤ 102 FFU/ml) in liver or brain from the ZIKV-3′UTR-
Δ20-LAV-infected mice, with other organs (except spleen)
exhibiting lower levels of the vaccine virus than those of the WT-
infected animals. At day 10 post infection, WT ZIKV-infected
mice retained viral loads in the heart, spleen, kidney, muscle,
testis, eye, and brain, whereas no organs from the ZIKV-3′UTR-
Δ20-LAV-infected mice had any detectable virus. Second, we
examined the potential adverse effect of ZIKV-3′UTR-Δ20-LAV
on the testis in 3-week-old A129 mice. As expected, at day 21 post
infection, WT ZIKV infection reduced testis weight and size
(Fig. 4b, c), lowered total and motile sperm counts (Fig. 4d, e),
and resulted in viral RNA in the shrunken testis (Fig. 4f). In
contrast, ZIKV-3′UTR-Δ20-LAV did not affect sperm counts or
testis weight and size (Fig. 4b–e), with no detectable viral RNA in
the testes (Fig. 4f). Third, we evaluated the neurovirulence of
ZIKV-3′UTR-Δ20-LAV through intracranial inoculation of 1-
day-old outbred, immunocompetent CD-1 mice (Fig. 4g). As
reported previously19, neonates succumbed to WT ZIKV infec-
tion; even a dose of only 10 FFU resulted in 13% mortality
(Fig. 4g). In contrast, no mortality was observed in mice that were
inoculated with 103 FFU of ZIKV-3′UTR-Δ20-LAV; however,
infection with 104 FFU of ZIKV-3′UTR-Δ20-LAV resulted in a
mortality rate of 29%. Fourth, we tested if the vaccine candidate
could infect Aedes aegyptimosquitoes, the main vector of ZIKV30,
31. After feeding on artiﬁcial blood-meals containing 106 FFU/ml
of ZIKV-3′UTR-Δ20-LAV or WT ZIKV, 50% of the engorged
mosquitoes were infected by WT ZIKV, whereas no mosquitoes
were infected by ZIKV-3′UTR-Δ20-LAV (Fig. 4h). Finally, we
tested the stability of ZIKV-3′UTR-Δ20-LAV in cell culture.
After continuous culture of ZIKV-3′UTR-Δ20-LAV on Vero cells
(an approved cell line for vaccine production32) for ﬁve rounds,
all recovered P5 viruses (derived from three independent
experiments) retained the 20-nucleotide deletion. However, the
P5 viruses accumulated additional mutations in the E- and NS1-
encoding genes (Supplementary Table 1), which may represent
Vero-cell-adaptive mutation(s) or compensatory mutation(s) to
3′UTR deletion. Further passaging of the viruses to P10 did not
change the 20-nucleotide deletion, indicating that the deletion is
stable in cell culture. Moreover, we passaged ZIKV-3′UTR-Δ20-
LAV in A129 mice for three rounds (3 days/round); all recovered
viruses retained the 20-nucleotide deletion, further suggesting the
stability of the mutant virus. Taken together, these results
demonstrate an excellent safety proﬁle of ZIKV-3′UTR-Δ20-
LAV, including limited, transient viral loads in mouse organs, no
adverse effect on testicular function, decreased neurovirulence,
incompetency to infect mosquitoes, and good stability.
Discussion
Our results showed that a single immunization of ZIKV-3′UTR-
Δ10-LAV prevented maternal-to-fetal transmission early during
pregnancy in C57BL/6 mice. Although no infectious challenge
virus was detected, very low levels of viral RNA were recovered
from ~30% of placentas and fetal heads from the vaccinated dams
after challenge; these breakthrough viral RNAs might derive from
stable antibody–virus complexes, which can last for several
days in vivo33. The clinical implications of such breakthrough
noninfectious viral RNA remain to be determined. In male A129
mice, a single-dose immunization of either ZIKV-3′UTR-Δ10-
LAV or ZIKV-3′UTR-Δ20-LAV prevented testis infection
and injury after challenge, indicating an additional beneﬁt of
vaccination to protect the male reproductive system. Notably,
unprotected young A129 mice (3 or 7 weeks old when infected)
infected with ZIKV developed smaller testes, whereas adult mice
(19 weeks old when infected) did not, suggesting that ZIKV
infection might cause more severe reproductive damage in
younger males. The clinical relevance of this observation remains
to be veriﬁed in NHPs and in humans. In NHPs, a single-dose
vaccination with ZIKV-3′UTR-Δ10-LAV or ZIKV-3′UTR-Δ20-
LAV induced sufﬁcient immune responses to prevent viremia,
with the ZIKV-3′UTR-Δ20-LAV eliciting greater immunogeni-
city, as reﬂected by its ability to induce sterilizing immunity
against challenge. One limitation of the current NHP results is the
low number of animals used for each vaccine candidates (n=
3–4). ZIKV vaccine-induced sterilizing immunity might be cri-
tical for protection against congenital abnormalities in humans.
Live-attenuated vaccines generally have the advantage of single
dose, rapid induction of durable immunity. Since ZIKV
is endemic primarily in low-income countries, a vaccine with
single-dose efﬁcacy is of practical importance, particularly when
controlling an explosive outbreak or immunizing populations in
remote areas where multiple doses and periodic boosting will be
challenging34. Thus, live-attenuated vaccines may be useful for
immunizing populations living in and traveling to ZIKV-endemic
areas. Besides our ZIKV-3′UTR-LAV, a single-dose immuniza-
tion with nucleoside-modiﬁed mRNA expressing ZIKV prM-E
(50 µg)18 or a recombinant rhesus adenovirus serotype 52 vector
expressing ZIKV prM-E (1011 viral particles)16 was also shown to
rapidly elicit antibody response and prevent viremia in NHPs;
whether these two vaccines achieved sterilizing immunity was not
determined. All other vaccine platforms, including inactivated
vaccine and prM-E DNA vaccine, need two immunizations to
ellicit robust antibody response for viremia protection in NHPs15,
16. It is conceivable that in immunocompromised individuals
and pregnant women, vaccination with live-attenuated virus
may be contraindicated to avoid potential adverse risks. These
individuals could be protected using inactivated, subunit, or gene-
based replication-defective vaccines. Therefore, there is a need
to develop multiple vaccine platforms in parallel to provide
complementary options for preventing and controlling ZIKV
infection and disease.
Methods
Experimental systems and measurements. Various in vivo systems were
employed to characterize the safety and efﬁcacy of vaccine candidates, including
C57BL/6J mouse pregnancy, A129 mouse testis protection, viral loading in A129
mouse organ, CD-1 mouse neurovirulence, and RMs efﬁcacy (see details below).
Since the protocols for each of these experimental systems have been previously
established (e.g., inoculum dose, infection route, challenge dose, and end-point
measurement), we did not attempt to change these optimized parameters when
testing our vaccine candidates. Therefore, different inoculum doses, challenge
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doses, and end-point measurements (e.g., qRT-PCR to measure viral RNA and
focus-forming assay to measure infection virus) were used in different in vivo
systems according to the established protocols. The detailed information is
described below and appropriately indicated in Results.
Ethics statement. Mouse studies were performed in accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocols were approved by the Institutional
Animal Care and Use Committee (IACUC) at the Washington University School of
Medicine (Assurance Number A3381-01) and the IACUC at the University of Texas
Medical Branch (UTMB; Protocol Number 0209068B). Dissections and footpad
injections were performed under anesthesia that was induced and maintained with
ketamine hydrochloride and xylazine at the Washington University or isoﬂurane at
UTMB. All efforts were made to minimize animal suffering. RMs experiments were
reviewed and approved by the Vaccine Research Center Animal Care and Use
Committee at the National Institute of Allergy and Infectious Diseases, the National
Institutes of Health. The NHP experiments were performed in compliance with the
pertinent regulations and policies from the National Institutes of Health.
Viruses and cells. The ZIKV Cambodian strain FSS13025 (GenBank number
KU955593.1) was produced from an infectious cDNA clone35. The ZIKV-3′UTR-
Δ10-LAV and ZIKV-3′UTR-Δ20-LAV strains were generated as described. The
Zika Puerto Rico strain PRVABC59 (GenBank number KU501215) and Dakar
41519 strain (GenBank number HQ234501.1) were obtained originally from
Dr Robert Tesh from the World Reference Center of Emerging Virus and Arbo-
viruses (WRCEVA) at UTMB. The mouse-adapted ZIKV-Dakar 41519 strain was
passaged twice in Rag1−/− mice (Jackson Laboratories) and as described pre-
viously29. Vero cells were purchased from the American Type Culture Collection
(CCL-81; Bethesda, MD, USA), and maintained at 37 °C with 5% CO2 in a high
glucose Dulbecco modiﬁed Eagle medium (DMEM; Invitrogen, Carlsbad, CA,
USA) with 10% fetal bovine serum (HyClone Laboratories, Logan, UT, USA) and
1% penicillin/streptomycin (Invitrogen). All cell lines tested negative for
mycoplasma.
Antibodies. The following antibodies were used in this study: anti-mouse Ifnar1
monoclonal antibody (clone MAR1-5A3; Leinco Technologies, Inc., St. Louis, MO,
USA); ZIKV-speciﬁc hyper-immune ascites ﬂuids (obtained from WRCEVA); anti-
mouse IgG antibody labeled with horseradish peroxidase (KPL, Gaithersburg, MD,
USA); and goat anti-mouse IgG conjugated with Alexa Fluor 488 (Thermo Fisher
Scientiﬁc, Providence, RI, USA).
A129 mouse experiment. A129 mice were bred in the animal facilities at UTMB.
All mice were housed in pathogen-free mouse facilities. Three-week- or 15-week-
old male A129 mice were infected with PBS (two sham groups), 104 FFU of ZIKV-
3′UTR-Δ10-LAV (Δ10), or 103 FFU of ZIKV-3′UTR-Δ20-LAV (Δ20). Mice were
anesthetized and bled via the retro orbital sinus for viremia testing. At day 28 post
immunization, mice were measured for neutralizing antibody titers using an
mCherry ZIKV infection assay19. On the same day, one sham group of PBS-
immunized mice and Δ10- and Δ20-immunized mice were challenge with 106 FFU
of ZIKV PRVABC59. Another sham group of mice was used as an unchallenged
negative control. At day 49 post immunization, mice were euthanized and
necropsied. Epididymis and testes were harvested immediately as previously
described36. Motile and nonmotile sperms were counted manually on a hemo-
cytometer by microscopy. Total sperm counts equal to the sum of motile and
nonmotile sperms. For quantiﬁcation of viral loads, testes were homogenized and
infectious viral levels were measured by a focus forming assay or qRT-PCR19. The
qRT-PCT primer/probe set includes forward primer (1193F: 5′-
CCGCTGCCCAACACAAG-3′), reverse primer (1269R: 5′-CCAC-
TAACGTTCTTTTGCAGACAT-3′), and probe (5′-FAM/AGCCTACCT/ZEN/
TGACAAGCAATCAGACACTCAA/3IABkFQ-3′). The probe contains a 5′-FAM
reporter dye, 3′ IBFQ quencher, and an internal ZEN quencher.
Mouse pregnancy experiment. C57BL/6J mice were bred and housed in patho-
gen-free mouse facilities at Washington University School of Medicine. One day
prior to immunization, the 8-week-old female C57BL/6J mice were dosed with
0.5 mg of anti-Ifnar1 antibody via an intraperitoneal route. Subsequently, mice
were subcutaneously inoculated in the footpad with 105 FFU of ZIKV-3′UTR-Δ10-
LAV or PBS sham. Immunized WT C57BL/6 female mice were mated with naive
WT male mice. At E5, pregnant dams were injected intraperitoneally with 2 mg of
anti-Ifnar1 antibody. On E6, mice were inoculated subcutaneously with 105 FFU of
mouse-adapted ZIKV Dakar 41519 via footpad injection. All animals were sacri-
ﬁced on E13 and analyzed for viral loads in placentas, fetuses, and maternal tissues.
Brieﬂy, maternal blood, organs from dams (brain and spleen), and fetuses (placenta
and fetal head) were collected. Serum was prepared after coagulation and cen-
trifugation. Organs were weighed and homogenized using a bead-beater apparatus
(MagNA Lyser, Roche). Viral RNA was extracted from serum and tissue samples
using the RNeasy Mini kit (Qiagen). The viral RNA levels were determined by
TaqMan one-step qRT-PCR on an ABI 7500 Fast Instrument using standard
cycling conditions. Viral burden is expressed on a log10 scale as viral RNA
equivalents per gram or per milliliter after comparison with a standard curve
produced using serial ﬁvefold dilutions of ZIKV RNA from known quantities of
infectious virus. The following primer/probe set was used for ZIKV qRT-PCR:
forward primer (1183F: 5′-CCACCAATGTTCTCTTGCAGACATATTG-3′),
reverse primer (1268R: 5′-TTCGGACAGCCGTTGTCCAACACAAG-3′), and
probe (1213F: 5′-56-FAM/AGCCTACCT TGACAAGCAGTC/3IABkFQ-3′).
Wherever indicated, viral burden for some samples was determined by focus-
forming assay on Vero cells20.
Quantiﬁcation of viral load in organs from A129 mice. A129 mice were infected
and organs were quantiﬁed for viral load using a focus-forming assay20. Viral RNA
in testis also was quantiﬁed by qRT-PCR. Brieﬂy, testes were harvested and placed
in DMEM with beads for homogenization. After homogenization, the supernatant
was used to extract viral RNA using RNeasy Mini kit (Qiagen). Extracted RNA was
eluted in 40 μl RNase-free water. qRT-PCR assays were performed on the Light-
Cycler 480 System (Roche) following the manufacturer’s protocol by using a 50 µl
reaction of the QuantiTect Probe RT-PCR Kit (Qiagen) and 10 µl RNA template.
The viral load was calculated based on a standard curve produced using serial 10-
fold dilutions of ZIKV RNA from known quantities of infectious virus. The qRT-
PCT primer/probe set includes forward primer (1193F: 5′-CCGCTGCCCAACA-
CAAG-3′), reverse primer (1269R: 5′-CCACTAACGTTCTTTTGCAGACAT-3′),
and probe (5′-FAM/AGCCTACCT/ZEN/TGACAAGCAATCAGACACTCAA/
3IABkFQ-3′). The probe contains a 5′-FAM reporter dye, 3′ IBFQ quencher, and
an internal ZEN quencher.
Vaccination of NHPs. RM (Macaca mulatta) experiments were performed at
Bioqual, Inc. (Rockville, MD, USA). All animal experiments were reviewed and
approved by the Animal Care and Use Committee of the Vaccine Research Center,
the National Institute of Allergy and Infectious Diseases, the National Institutes of
Health. Animals were housed and cared in accordance with local, state, federal, and
institutional policies in an American Association for Accreditation of Laboratory
Animal Care-accredited facility at the Bioqual Inc. RMs (3–4/group) were rando-
mized by body weight, gender, and age, and subcutaneously administered with 103
FFU of parental WT ZIKV strain FSS13025, ZIKV-3′UTR-Δ10-LAV, ZIKV-3′
UTR-Δ20-LAV, or PBS sham at day 0. Blood was collected at days 2, 3, 4, 5, 7, and
10 for viremia testing and weekly for analysis of antibody responses by an mCherry
ZIKV neutralization assay19, 37. The immunized animals were subcutaneously
challenged with 103 FFU of ZIKV strain PRVABC59 at week 8. Blood samples
were collected for determination of viral load at days 2, 3, 4, 5, 7, and 10, and
neutralizing antibody at weeks 2, 4, and 6 post challenge.
Viremia from RMs was quantiﬁed by a qRT-PCR assay and focus-forming assay
as described in the proceeding section. For qRT-PCR quantiﬁcation, viral RNA was
extracted from rhesus serum using QIAamp Viral RNA Kits (Qiagen) following the
manufacturer’s instruction. Extracted RNA was eluted in 40 μl RNase-free water.
qRT-PCR assay was performed as described above. In vitro-transcribed full-length
ZIKV RNA was used as a standard for qRT-PCR quantiﬁcation. The primer/probe
set is described in the proceeding section.
Neutralization assay and neurovirulance. All antibody neutralization titers were
determined using an mCherry ZIKV as previously reported19. The serum dilution
that neutralized 50% of mCherry ZIKV infection (NT50) were presented. For
measuring neurovirulence, 1-day-old outbred CD-1 mice (Charles River) were
injected intracranially with indicated amounts of viruses. The infected mice were
monitored for morbidity and mortality as reported previously19.
Mosquito infection. For measuring mosquito infection, artiﬁcial blood-meal spiked
with 106 FFU/ml of indicated viruses was used to feed A. aegypti mosquitoes (derived
from a stock isolated in Galveston, TX, USA), and engorged mosquitoes were incu-
bated at 28 °C, 80% relative humidity on a 12:12 h light:dark cycle with ad libitum
access to 10% sucrose. The infection rates were determined at day 7 post feeding as
reported previously35.
Data analysis. All data were analyzed with GraphPad Prism v7.02 software. Data
are expressed as the mean ± SD. Comparisons of groups were performed using
Mann–Whitney test or one-way analysis of variance with a multiple comparisons
correction. A P-value of < 0.05 indicates statistical signiﬁcance.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles, or are
available from the authors upon request.
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